At this panel from Ending Age-Related Diseases 2020, Javier Noris of Lifespan.io talks with Patrick Burgermeister of Kizoo Ventures, Reason of Repair Biotechnologies, Sergio Ruiz of Methuselah Labs, and Ronjon Nag of Institute R42 about the valley of death in biotech investment. Early-stage research is funded by universities and governments, and companies are funded by investors, but it is difficult for researchers to bring their findings to the level at which investors would be interested, and being unable to cross this valley of death is a significant hindrance for the development of rejuvenation biotechnology. Being able to reliably overcome this would be a major benefit for the development of therapies that directly target the root causes of aging.
HELP SPREAD THE WORD
Please connect with us on social media, like and share our content, and help us build grass-roots support for healthy life extension:
Journal Club returns live to our Facebook channel on June 29th at noon Eastern Time with Dr. Oliver Medvedik. This month, we are taking a look at rapamycin, a drug that has long been believed to slow down […]
With a new announcement from IBM and Germany’s Fraunhofer Institute, the era of quantum computing has finally arrived in Europe. Can its advance speed up the discovery of new drugs? […]
There are few things as tasty as a good blueberry, but science is showing that there could be more health benefits to this delicious fruit than people might think. What is Pterostilbene? Pterostilbene (trans-3,5-dimethoxy-4-hydroxystilbene) is a naturally […]
A new review published in the American Journal of Respiratory Cell and Molecular Biology discusses the causes of, and potential treatments for, idiopathic pulmonary fibrosis […]
Every day, researchers get together in their labs and try to find ways of bringing aging under medical control. Despite the ongoing global effort, it is estimated that a relatively complete system of controlling biological aging is at […]
Write a comment: